172 results on '"Curry WT"'
Search Results
2. Syndrome of inappropriate antidiuretic hormone secretion in patients with olfactory neuroblastoma.
- Author
-
Gray ST, Holbrook EH, Najm MH, Sadow PM, Curry WT, and Lin DT
- Published
- 2012
3. The bipedicled anterior septal flap: a radioanatomic and cadaveric study.
- Author
-
Bleier BS, Curry WT, Wang EW, Schlosser RJ, Bleier, Benjamin S, Curry, William T, Wang, Eric W, and Schlosser, Rodney J
- Abstract
Objectives/hypothesis: Pedicled mucosal flaps are the preferred method of endoscopic skull base reconstruction. Vascularized coverage of the anterior and posterior frontal tables remains a challenge given the lack of large caliber vessels supplying the anterior septum. The objective of this study was to define a novel bipedicled anterior septal (BAS) flap that is hypothesized to be capable of providing reproducible coverage of these difficult areas.Study Design: Radioanatomic and cadaveric study.Methods: The flap outline was superimposed over nine midline sagittal computed tomography images. The pedicles are comprised of the septal branch of the superior labial artery and the nasopalatine artery. The flap length subtended the distance from the incisive canal to the sphenoid face at the level of the choanal arch. Radiometric analysis of the flap length to base ratio and anterior/posterior frontal table coverage were calculated. These projected values were confirmed in four cadaveric dissection specimens.Results: The mean flap length was 39.64 ± 4.26 mm with a mean length:base ratio of 3.29 ± 0.70 and a total surface area of 916.46 ± 262.66 mm(2) . The flap was estimated to provide coverage of 100.31 ± 21.34% of the frontal beak and 50.74 ± 32.54% of the posterior frontal table. In all cadaveric specimens the flap extended beyond the superior aspect of the frontal beak and at least 50% of the posterior table.Conclusions: The BAS flap represents a novel septal mucosal flap based on two well-defined arterial inputs. This flap is capable of providing reliable vascularized coverage of the posterior frontal table and the frontal beak following frontal drillout. [ABSTRACT FROM AUTHOR]- Published
- 2011
- Full Text
- View/download PDF
4. The variability of stimulus thresholds in electrophysiologic cortical language mapping.
- Author
-
Wang SG, Eskandar EN, Kilbride R, Chiappa KH, Curry WT, Williams Z, and Simon MV
- Published
- 2011
- Full Text
- View/download PDF
5. Hypertrophic anterior cervical osteophytes causing dysphagia and airway obstruction.
- Author
-
Lin HW, Quesnel AM, Holman AS, Curry WT Jr., and Rho MB
- Abstract
Hyperostosis of anterior cervical vertebral osteophytes can produce otolaryngological symptoms ranging from mild dysphagia, dysphonia, and foreign body sensation to severe food impaction and stridulous dyspnea. Airway compromise necessitating a tracheostomy is very rare. We discuss the case of an elderly man who presented with progressive dysphagia and a large hypopharyngeal mass as his initial manifestations of hypertrophic anterior cervical osteophytes. After a biopsy of the mass, the patient went into airway distress due to bilateral vocal fold fixation by the enlarging mass and consequently required a surgical airway. A combined team approach to the removal of the osteophytes successfully resolved his symptoms. The clinical, diagnostic, radiologic, and therapeutic principles involved in this case are presented and discussed. The recognition of hypertrophic osteophytes as a potential cause of common otolaryngological symptoms in the elderly population is paramount, as these symptoms can rapidly progress and lead to life-threatening airway obstruction. Medical and surgical interventions can be employed for the treatment of hypertrophic anterior cervical osteophytes, and they often result in favorable outcomes. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
6. Microenvironmental correlates of immune checkpoint inhibitor response in human melanoma brain metastases revealed by T cell receptor and single-cell RNA sequencing
- Author
-
Alvarez-Breckenridge, CA, primary, Markson, SC, additional, Stocking, JH, additional, Nayyar, N, additional, Lastrapes, M, additional, Strickland, MR, additional, Kim, AE, additional, de Sauvage, M, additional, Dahal, A, additional, Larson, JM, additional, Mora, JL, additional, Navia, AW, additional, Kuter, BM, additional, Gill, CM, additional, Bertalan, MS, additional, Shaw, B, additional, Kaplan, A, additional, Subramanian, M, additional, Jain, A, additional, Kumar, S, additional, White, M, additional, Shahid, O, additional, Pauken, KE, additional, Miller, BC, additional, Izar, B, additional, Davies, M, additional, Frederick, DT, additional, Boland, GM, additional, Herbert, C, additional, Shaw, M, additional, Martinez-Lage, M, additional, Frosch, MP, additional, Wang, N, additional, Gerstner, ER, additional, Nahed, BV, additional, Curry, WT, additional, Carter, BC, additional, Cahill, DP, additional, Sharpe, A, additional, Suvà, ML, additional, Sullivan, RJ, additional, Brastianos, PK, additional, and Carter, SL, additional
- Full Text
- View/download PDF
7. Case records of the Massachusetts General Hospital. Case 20-2007. An 11-year-old boy with a calcified mass in the nose.
- Author
-
Cunningham MJ, Lin DT, Curry WT Jr., Ebb DH, Yock TI, Curtin HD, Faquin WC, Cunningham, Michael J, Lin, Derrick T, Curry, William T Jr, Ebb, David H, Yock, Torunn I, Curtin, Hugh D, and Faquin, William C
- Published
- 2007
8. Mutant IDH Modulates Suppressive Myeloid Populations in Malignant Glioma.
- Author
-
Grewal EP, Richardson LGK, Sun J, Ramapriyan R, Martinez-Lage M, Miller JJ, Carter BS, Cahill DP, Curry WT, and Choi BD
- Subjects
- Animals, Humans, Mice, Cell Line, Tumor, Myeloid Cells pathology, Myeloid Cells metabolism, Gene Expression Regulation, Neoplastic, Disease Models, Animal, Transcriptome, Isocitrate Dehydrogenase genetics, Mutation, Glioma genetics, Glioma pathology, Myeloid-Derived Suppressor Cells metabolism, Brain Neoplasms genetics, Brain Neoplasms pathology
- Abstract
Purpose: Mutations in the isocitrate dehydrogenase (IDH) genes IDH1 and IDH2 have critical diagnostic and prognostic significance in diffuse gliomas. Neomorphic mutant IDH activity has been previously implicated in T-cell suppression; however, the effects of IDH mutations on intratumoral myeloid populations remain underexplored. In this study, we investigate the influence of IDH status on the myeloid compartment using human glioma specimens and preclinical models., Experimental Design: We performed RNA sequencing and quantitative immunofluorescence on newly diagnosed, treatment-naive IDH-mutant grade 4 astrocytoma and IDH-wild-type (IDH-WT) glioblastoma (GBM) specimens. We also generated a syngeneic murine model, comparing transcriptomic and cell-level changes in paired isogenic glioma lines that differ only in IDH mutational status., Results: Among patient samples, IDH-mutant tumors displayed an underrepresentation of suppressive myeloid transcriptional signatures, which was confirmed at the cellular level with decreased numbers of intratumoral M2-like macrophages and myeloid-derived suppressor cells. Introduction of the mutant IDH enzyme into murine glioma was sufficient to recapitulate the transcriptomic and cellular shifts observed in patient samples., Conclusions: We provide transcriptomic and cellular evidence that mutant IDH is associated with a quantitative reduction of suppressive myeloid cells in gliomas and that introduction of the mutant enzyme is sufficient to result in corresponding cellular changes using an in vivo preclinical model. These data advance our understanding of high-grade gliomas by identifying key myeloid cell populations that are reprogrammed by mutant IDH and may be targetable through therapeutic approaches., (©2024 American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
9. Radical surgical resection with molecular margins is associated with improved survival in IDH wild-type glioblastoma.
- Author
-
Massaad E, Smith WJ, Bradley J, Esposito E, Gupta M, Burns E, Burns R, Velarde JK, Berglar IK, Gupta R, Martinez-Lage M, Dietrich J, Lennerz JK, Dunn GP, Jones PS, Choi BD, Kim AE, Frosch M, Barker FG, Curry WT, Carter BS, Nahed BV, Cahill DP, and Shankar GM
- Subjects
- Humans, Male, Female, Middle Aged, Telomerase genetics, Retrospective Studies, Aged, Survival Rate, Prospective Studies, Adult, Prognosis, Follow-Up Studies, Neurosurgical Procedures methods, Promoter Regions, Genetic, Glioblastoma surgery, Glioblastoma genetics, Glioblastoma pathology, Glioblastoma mortality, Glioblastoma diagnostic imaging, Isocitrate Dehydrogenase genetics, Brain Neoplasms surgery, Brain Neoplasms genetics, Brain Neoplasms pathology, Brain Neoplasms mortality, Brain Neoplasms diagnostic imaging, Mutation, Margins of Excision
- Abstract
Background: Survival is variable in patients with glioblastoma IDH wild-type (GBM), even after comparable surgical resection of radiographically detectable disease, highlighting the limitations of radiographic assessment of infiltrative tumor anatomy. The majority of postsurgical progressive events are failures within 2 cm of the resection margin, motivating supramaximal resection strategies to improve local control. However, which patients benefit from such radical resections remains unknown., Methods: We developed a predictive model to identify which IDH wild-type GBMs are amenable to radiographic gross-total resection (GTR). We then investigated whether GBM survival heterogeneity following GTR is correlated with microscopic tumor burden by analyzing tumor cell content at the surgical margin with a rapid qPCR-based method for detection of TERT promoter mutation., Results: Our predictive model for achievable GTR, developed on retrospective radiographic and molecular data of GBM patients undergoing resection, had an area under the curve of 0.83, sensitivity of 62%, and specificity of 90%. Prospective analysis of this model in 44 patients found that 89% of patients were correctly predicted to achieve a residual volume (RV) < 4.9cc. Of the 44 prospective patients undergoing rapid qPCR TERT promoter mutation analysis at the surgical margin, 7 had undetectable TERT mutation, of which 5 also had a GTR (RV < 1cc). In these 5 patients at 30 months follow-up, 75% showed no progression, compared to 0% in the group with TERT mutations detected at the surgical margin (P = .02)., Conclusions: These findings identify a subset of patients with GBM that may derive local control benefits from radical resection to undetectable molecular margins., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
10. Rapid tumor DNA analysis of cerebrospinal fluid accelerates treatment of central nervous system lymphoma.
- Author
-
Gupta M, Bradley JD, Massaad E, Burns EJ, Georgantas NZ, Maron GE, Batten JM, Gallagher A, Thierauf J, Nayyar N, Gordon A, Jones SS, Pisapia M, Sun Y, Jones PS, Barker FG 2nd, Curry WT, Gupta R, Romero JM, Wang N, Brastianos PK, Martinez-Lage M, Tateishi K, Forst DA, Nahed BV, Batchelor TT, Ritterhouse LL, Iser F, Kessler T, Jordan JT, Dietrich J, Meyerson M, Cahill DP, Lennerz JK, Carter BS, and Shankar GM
- Subjects
- Humans, Female, Male, Middle Aged, Aged, Adult, DNA, Neoplasm cerebrospinal fluid, DNA, Neoplasm genetics, Aged, 80 and over, Mutation, Prospective Studies, Young Adult, Central Nervous System Neoplasms cerebrospinal fluid, Central Nervous System Neoplasms genetics, Central Nervous System Neoplasms diagnosis, Central Nervous System Neoplasms therapy, Lymphoma cerebrospinal fluid, Lymphoma genetics, Lymphoma diagnosis, Lymphoma therapy
- Abstract
Abstract: Delays and risks associated with neurosurgical biopsies preclude timely diagnosis and treatment of central nervous system (CNS) lymphoma and other CNS neoplasms. We prospectively integrated targeted rapid genotyping of cerebrospinal fluid (CSF) into the evaluation of 70 patients with CNS lesions of unknown cause. Participants underwent genotyping of CSF-derived DNA using a quantitative polymerase chain reaction-based approach for parallel detection of single-nucleotide variants in the MYD88, TERT promoter, IDH1, IDH2, BRAF, and H3F3A genes within 80 minutes of sample acquisition. Canonical mutations were detected in 42% of patients with neoplasms, including cases of primary and secondary CNS lymphoma, glioblastoma, IDH-mutant brainstem glioma, and H3K27M-mutant diffuse midline glioma. Genotyping results eliminated the need for surgical biopsies in 7 of 33 cases (21.2%) of newly diagnosed neoplasms, resulting in significantly accelerated initiation of disease-directed treatment (median, 3 vs 12 days; P = .027). This assay was then implemented in a Clinical Laboratory Improvement Amendments environment, with 2-day median turnaround for diagnosis of CNS lymphoma from 66 patients across 4 clinical sites. Our study prospectively demonstrates that targeted rapid CSF genotyping influences oncologic management for suspected CNS tumors., (© 2024 American Society of Hematology. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.)
- Published
- 2024
- Full Text
- View/download PDF
11. Pre-Clinical Models for CAR T-Cell Therapy for Glioma.
- Author
-
Vandecandelaere G, Ramapriyan R, Gaffey M, Richardson LG, Steuart SJ, Tazhibi M, Kalaw A, Grewal EP, Sun J, Curry WT, and Choi BD
- Subjects
- Humans, Animals, T-Lymphocytes immunology, Disease Models, Animal, Receptors, Antigen, T-Cell metabolism, Receptors, Antigen, T-Cell immunology, Glioma therapy, Glioma immunology, Glioma pathology, Immunotherapy, Adoptive methods, Brain Neoplasms therapy, Brain Neoplasms immunology, Brain Neoplasms pathology, Receptors, Chimeric Antigen immunology, Receptors, Chimeric Antigen metabolism
- Abstract
Immunotherapy represents a transformative shift in cancer treatment. Among myriad immune-based approaches, chimeric antigen receptor (CAR) T-cell therapy has shown promising results in treating hematological malignancies. Despite aggressive treatment options, the prognosis for patients with malignant brain tumors remains poor. Research leveraging CAR T-cell therapy for brain tumors has surged in recent years. Pre-clinical models are crucial in evaluating the safety and efficacy of these therapies before they advance to clinical trials. However, current models recapitulate the human tumor environment to varying degrees. Novel in vitro and in vivo techniques offer the opportunity to validate CAR T-cell therapies but also have limitations. By evaluating the strengths and weaknesses of various pre-clinical glioma models, this review aims to provide a roadmap for the development and pre-clinical testing of CAR T-cell therapies for brain tumors.
- Published
- 2024
- Full Text
- View/download PDF
12. Altered cancer metabolism and implications for next-generation CAR T-cell therapies.
- Author
-
Ramapriyan R, Vykunta VS, Vandecandelaere G, Richardson LGK, Sun J, Curry WT, and Choi BD
- Subjects
- Humans, Animals, T-Lymphocytes immunology, Neoplasms therapy, Neoplasms immunology, Immunotherapy, Adoptive methods, Tumor Microenvironment immunology, Receptors, Chimeric Antigen immunology
- Abstract
This review critically examines the evolving landscape of chimeric antigen receptor (CAR) T-cell therapy in treating solid tumors, with a particular focus on the metabolic challenges within the tumor microenvironment. CAR T-cell therapy has demonstrated remarkable success in hematologic malignancies, yet its efficacy in solid tumors remains limited. A significant barrier is the hostile milieu of the tumor microenvironment, which impairs CAR T-cell survival and function. This review delves into the metabolic adaptations of cancer cells and their impact on immune cells, highlighting the competition for nutrients and the accumulation of immunosuppressive metabolites. It also explores emerging strategies to enhance CAR T-cell metabolic fitness and persistence, including genetic engineering and metabolic reprogramming. An integrated approach, combining metabolic interventions with CAR T-cell therapy, has the potential to overcome these constraints and improve therapeutic outcomes in solid tumors., (Copyright © 2024 Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
13. Infusion of CARv3-TEAM-E T Cells in Glioblastoma. Reply.
- Author
-
Gerstner ER, Choi BD, and Curry WT
- Subjects
- Humans, Receptors, Chimeric Antigen, Clinical Trials, Phase I as Topic, Brain Diseases drug therapy, Brain Diseases etiology, Dexamethasone therapeutic use, Bevacizumab adverse effects, Bevacizumab therapeutic use, Brain Neoplasms therapy, Glioblastoma therapy, Immunotherapy, Adoptive adverse effects, Immunotherapy, Adoptive methods, T-Lymphocytes immunology
- Published
- 2024
- Full Text
- View/download PDF
14. Intraventricular CARv3-TEAM-E T Cells in Recurrent Glioblastoma.
- Author
-
Choi BD, Gerstner ER, Frigault MJ, Leick MB, Mount CW, Balaj L, Nikiforow S, Carter BS, Curry WT, Gallagher K, and Maus MV
- Subjects
- Humans, CD8-Positive T-Lymphocytes metabolism, Neoplasm Recurrence, Local therapy, ErbB Receptors antagonists & inhibitors, ErbB Receptors genetics, ErbB Receptors metabolism, Glioblastoma therapy, Glioblastoma pathology, Immunotherapy, Adoptive adverse effects, Receptors, Antigen, T-Cell genetics, Receptors, Antigen, T-Cell therapeutic use, Receptors, Chimeric Antigen therapeutic use
- Abstract
In this first-in-human, investigator-initiated, open-label study, three participants with recurrent glioblastoma were treated with CARv3-TEAM-E T cells, which are chimeric antigen receptor (CAR) T cells engineered to target the epidermal growth factor receptor (EGFR) variant III tumor-specific antigen, as well as the wild-type EGFR protein, through secretion of a T-cell-engaging antibody molecule (TEAM). Treatment with CARv3-TEAM-E T cells did not result in adverse events greater than grade 3 or dose-limiting toxic effects. Radiographic tumor regression was dramatic and rapid, occurring within days after receipt of a single intraventricular infusion, but the responses were transient in two of the three participants. (Funded by Gateway for Cancer Research and others; INCIPIENT ClinicalTrials.gov number, NCT05660369.)., (Copyright © 2024 Massachusetts Medical Society.)
- Published
- 2024
- Full Text
- View/download PDF
15. Endoscopic endonasal approach for olfactory groove meningioma resection: Strategies and outcomes in a retrospective case series.
- Author
-
Wang AJ, Lee CK, Blanch M, Talati PA, Gray ST, Bleier BS, Scangas GA, Holbrook EH, and Curry WT
- Subjects
- Humans, Nasal Cavity diagnostic imaging, Nasal Cavity surgery, Nose surgery, Nose pathology, Retrospective Studies, Treatment Outcome, Meningeal Neoplasms diagnostic imaging, Meningeal Neoplasms surgery, Meningioma diagnostic imaging, Meningioma surgery, Meningioma pathology, Skull Base Neoplasms diagnostic imaging, Skull Base Neoplasms surgery
- Abstract
Objective: Though the endoscopic endonasal approach (EEA) is a widely accepted treatment for skull base tumors, the specific use of EEA for olfactory groove meningiomas (OGMs) is debated, with variable outcomes reported in the literature. We review the surgical results of OGM resections for one surgeon including the operative approach, surgical nuances, and outcomes, with a focus on factors relating to patient selection which favor EEA over transcranial approaches., Methods: We retrospectively reviewed thirteen cases of endoscopic endonasal resection of olfactory groove meningiomas. Patient characteristics, clinical characteristics, surgical outcomes, and complications were analyzed. Extent of resection was determined based on volumetric analysis of pre- and postoperative MRI., Results: Anatomic characteristics that render a tumor difficult to access fully are lateral extension beyond the mid-orbit and anterior extension to the falx. Simpson Grade I resection was achieved in 11/13 (84.6 %) cases. Mean pre-operative tumor volume was 8.99 cm
3 (range 2.19-16.79 cm3 ), and 92 % of tumors were WHO grade I. We demonstrate 2 cases of smell preservation, possible with small unilateral tumors and tumors that are confined to either the anterior or posterior portion of the cribriform plate. The post-operative CSF leak rate was 7.7 %, without prophylactic lumbar CSF drainage. The mortality rate was 7.7 % (n = 1) after infectious complications following CSF leak., Conclusions: Endoscopic endonasal resection of olfactory groove meningiomas is an effective and safe operative method with outcomes and complication rates comparable to transcranial approaches. Key considerations include careful patient selection and familiarity with technical nuances of endoscopic endonasal approach for this specific tumor type., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
16. Fluorescence and immune-cell infiltration of nonneoplastic, postbrachytherapy brain tissue in 5-ALA-guided resection of recurrent anaplastic meningioma: illustrative case.
- Author
-
Ramapriyan R, Clark VE, Martinez-Lage M, Hsueh B, Nahed BV, Curry WT, Choi BD, and Carter BS
- Abstract
Background: 5-Aminolevulinic acid (5-ALA) fluorescence-guided surgery is a well-established technique for resecting high-grade gliomas. However, its application in meningiomas, especially those previously treated with radiation therapy, remains under investigation., Observations: A 48-year-old female with recurrent anaplastic meningioma, World Health Organization grade 3, underwent a right-sided craniotomy using off-label 5-ALA as a surgical adjunct. The patient had previously undergone brachytherapy seed implantation (20 × cesium 131) for tumor management. During the surgery, a large fluorescent tumor mass adjacent to the brachytherapy-treated area was resected, and the prior brachytherapy seeds were removed. Interestingly, the surrounding brain tissue in the irradiated area showed robust 5-ALA fluorescence. Pathological examination confirmed that the fluorescent brain tissue was nonneoplastic and associated with lymphocyte and macrophage infiltration., Lessons: This case report presents unique 5-ALA fluorescence in nonneoplastic tissue following brachytherapy, which was found during the resection of recurrent anaplastic meningioma. This phenomenon may reflect an intricate interplay among radiation therapy, immune cells, the tumor microenvironment, and 5-ALA metabolism. Given that false-positive findings in fluorescence-guided surgery can lead to unnecessary tissue resection and increased surgical morbidity, further research is warranted to elucidate the mechanisms underlying this phenomenon and its implications for meningioma surgery.
- Published
- 2024
- Full Text
- View/download PDF
17. Suppression of antitumor immune signatures and upregulation of VEGFA as IDH-mutant gliomas progress to higher grade.
- Author
-
Grewal EP, Richardson LGK, Sun J, Ramapriyan R, Martinez-Lage M, Miller JJ, Cahill DP, Choi BD, and Curry WT
- Subjects
- Humans, Isocitrate Dehydrogenase genetics, Up-Regulation, Mutation genetics, Tumor Microenvironment genetics, Vascular Endothelial Growth Factor A genetics, Vascular Endothelial Growth Factor A metabolism, Brain Neoplasms genetics, Brain Neoplasms surgery, Brain Neoplasms pathology, Glioma genetics, Glioma pathology, Glioblastoma, Astrocytoma genetics
- Abstract
Objective: Several studies have compared the immune microenvironment of isocitrate dehydrogenase (IDH)-wildtype glioma versus IDH-mutant glioma. The authors sought to determine whether histological tumor progression in a subset of IDH-mutant glioma was associated with concomitant alterations in the intratumoral immune microenvironment., Methods: The authors performed bulk RNA sequencing on paired and unpaired samples from patients with IDH-mutant glioma who underwent surgery for tumor progression across multiple timepoints. They compared patterns of differential gene expression, overall inflammatory signatures, and transcriptomic measures of relative immune cell proportions., Results: A total of 55 unique IDH-mutant glioma samples were included in the analysis. The authors identified multiple genes associated with progression and higher grade across IDH-mutant oligodendrogliomas and astrocytomas. Compared with lower-grade paired samples, grade 4 IDH-mutant astrocytomas uniquely demonstrated upregulation of VEGFA in addition to counterproductive alterations in inflammatory score reflective of a more hostile immune microenvironment., Conclusions: Here, the authors have provided a transcriptomic analysis of a progression cohort for IDH-mutant glioma. Compared with lower-grade tumors, grade 4 astrocytomas displayed alterations that may inform the timing of antiangiogenic and immune-based therapy as these tumors progress.
- Published
- 2024
- Full Text
- View/download PDF
18. Utility of cortical tissue analysis in normal pressure hydrocephalus.
- Author
-
Greenberg ABW, Mekbib KY, Mehta NH, Kiziltug E, Duy PQ, Smith HR, Junkkari A, Leinonen V, Hyman BT, Chan D, Curry WT Jr, Arnold SE, Barker Ii FG, Frosch MP, and Kahle KT
- Subjects
- Humans, Cerebral Cortex pathology, Alzheimer Disease, Hydrocephalus, Normal Pressure surgery, Hydrocephalus, Normal Pressure pathology
- Abstract
Clinical improvement following neurosurgical cerebrospinal fluid shunting for presumed idiopathic normal pressure hydrocephalus is variable. Idiopathic normal pressure hydrocephalus patients may have undetected Alzheimer's disease-related cortical pathology that confounds diagnosis and clinical outcomes. In this study, we sought to determine the utility of cortical tissue immuno-analysis in predicting shunting outcomes in idiopathic normal pressure hydrocephalus patients. We performed a pooled analysis using a systematic review as well as analysis of a new, original patient cohort. Of the 2707 screened studies, 3 studies with a total of 229 idiopathic normal pressure hydrocephalus patients were selected for inclusion in this meta-analysis alongside our original cohort. Pooled statistics of shunting outcomes for the 229 idiopathic normal pressure hydrocephalus patients and our new cohort of 36 idiopathic normal pressure hydrocephalus patients revealed that patients with Aβ + pathology were significantly more likely to exhibit shunt nonresponsiveness than patients with negative pathology. Idiopathic normal pressure hydrocephalus patients with Alzheimer's disease -related cortical pathology may be at a higher risk of treatment facing unfavorable outcomes following cerebrospinal fluid shunting. Thus, cortical tissue analysis from living patients may be a useful diagnostic and prognostic adjunct for patients with presumed idiopathic normal pressure hydrocephalus and potentially other neurodegenerative conditions affecting the cerebral cortex., (© The Author(s) 2024. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
19. Cases of familial idiopathic normal pressure hydrocephalus implicate genetic factors in disease pathogenesis.
- Author
-
Greenberg ABW, Mehta NH, Mekbib KY, Kiziltug E, Smith HR, Hyman BT, Chan D, Curry WT Jr, Arnold SE, Frosch MP, Duy PQ, and Kahle KT
- Subjects
- Humans, Prognosis, Biomarkers cerebrospinal fluid, Amyloid beta-Peptides cerebrospinal fluid, Hydrocephalus, Normal Pressure genetics, Hydrocephalus, Normal Pressure surgery, Hydrocephalus, Normal Pressure cerebrospinal fluid
- Abstract
Idiopathic normal pressure hydrocephalus is a disorder of unknown pathophysiology whose diagnosis is paradoxically made by a positive response to its proposed treatment with cerebrospinal fluid diversion. There are currently no idiopathic normal pressure hydrocephalus disease genes or biomarkers. A systematic analysis of familial idiopathic normal pressure hydrocephalus could aid in clinical diagnosis, prognosis, and treatment stratification, and elucidate disease patho-etiology. In this 2-part analysis, we review literature-based evidence for inheritance of idiopathic normal pressure hydrocephalus in 22 pedigrees, and then present a novel case series of 8 familial idiopathic normal pressure hydrocephalus patients. For the case series, demographics, familial history, pre- and post-operative symptoms, and cortical pathology were collected. All novel familial idiopathic normal pressure hydrocephalus patients exhibited improvement following shunt treatment and absence of neurodegenerative cortical pathology (amyloid-beta and hyperphosphorylated tau), in contrast to many sporadic cases of idiopathic normal pressure hydrocephalus with variable clinical responses. Analysis of the 30 total familial idiopathic normal pressure hydrocephalus cases reported herein is highly suggestive of an autosomal dominant mechanism of inheritance. This largest-ever presentation of multiply affected idiopathic normal pressure hydrocephalus pedigrees provides strong evidence for Mendelian inheritance and autosomal dominant transmission of an idiopathic normal pressure hydrocephalus trait in a subset of patients that positively respond to shunting and lack neurodegenerative pathology. Genomic investigation of these families may identify the first bona fide idiopathic normal pressure hydrocephalus disease gene., (© The Author(s) 2023. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2023
- Full Text
- View/download PDF
20. The Role of Antibody-Based Therapies in Neuro-Oncology.
- Author
-
Ramapriyan R, Sun J, Curry A, Richardson LG, Ramesh T, Gaffey MA, Gedeon PC, Gerstner ER, Curry WT, and Choi BD
- Abstract
This review explores the evolving landscape of antibody-based therapies in neuro-oncology, in particular, immune checkpoint inhibitors and immunomodulatory antibodies. We discuss their mechanisms of action, blood-brain barrier (BBB) penetration, and experience in neuro-oncological conditions. Evidence from recent trials indicates that while these therapies can modulate the tumor immune microenvironment, their clinical benefits remain uncertain, largely due to challenges with BBB penetration and tumor-derived immunosuppression. This review also examines emerging targets such as TIGIT and LAG3, the potential of antibodies in modulating the myeloid compartment, and tumor-specific targets for monoclonal antibody therapy. We further delve into advanced strategies such as antibody-drug conjugates and bispecific T cell engagers. Lastly, we explore innovative techniques being investigated to enhance antibody delivery, including CAR T cell therapy. Despite current limitations, these therapies hold significant therapeutic potential for neuro-oncology. Future research should focus on optimizing antibody delivery to the CNS, identifying novel biological targets, and discovering combination therapies to address the hostile tumor microenvironment.
- Published
- 2023
- Full Text
- View/download PDF
21. County-level disparities in care for patients with glioblastoma.
- Author
-
Ramapriyan R, Ramesh T, Yu H, Richardson LG, Nahed BV, Carter BS, Barker FG, Curry WT, and Choi BD
- Subjects
- Humans, United States epidemiology, Cross-Sectional Studies, Socioeconomic Factors, Health Resources, Glioblastoma epidemiology, Glioblastoma surgery, Brain Neoplasms epidemiology, Brain Neoplasms surgery
- Abstract
Objective: Racial and socioeconomic disparities in neuro-oncological care for patients with brain tumors remain underexplored. This study aimed to analyze county-level disparities in glioblastoma (GBM) care in the United States, focusing on access to surgery and the use of adjuvant temozolomide chemotherapy and radiation therapy., Methods: Using repeated cross-sectional data from the Surveillance, Epidemiology, and End Results 17 database; the Area Health Resources File; and the American Community Survey, from 2010 to 2019, the authors performed multivariate regression analyses to understand the associations between county-level racial and socioeconomic characteristics, as well as the rates of surgery performed, delays in surgery, and use of adjuvant chemotherapy and radiation therapy for newly diagnosed GBM., Results: In total, 29,609 GBM patients from 602 different US counties over a decade were included in this study. Counties with lower rates of surgery for GBM were associated with a higher percentage of Black residents (coefficient [CE] -0.001, 95% CI -0.002 to 0; p < 0.05) and being located in the Midwest (CE -0.132, 95% CI -0.195 to -0.069; p < 0.001) or West (CE -0.127, 95% CI -0.189 to -0.065; p < 0.001) relative to the Northeast. Counties with delayed surgical treatment were more likely to lack neurosurgeons (adjusted OR [aOR] 2.52, 95% CI 1.77-3.60; p < 0.001), have a higher percentage of Black residents (aOR 1.011, 95% CI 1.00-1.02; p < 0.05), and be located in the Midwest (aOR 3.042, 95% CI 1.12-8.24; p < 0.05) or West (aOR 3.175, 95% CI 1.12-8.97 p < 0.05). Counties with high rates of adjuvant radiation therapy were less likely to have higher percentages of Black residents (aOR 0.987, 95% CI 0.980-0.995; p < 0.01) and uninsured individuals (aOR 0.962, 95% CI 0.937-0.987; p < 0.01)., Conclusions: Counties without neurosurgeons and those with a higher percentage of Black patients have delays in surgical care and demonstrate lower overall rates of surgery and adjuvant therapy for GBM. This study underscores the need for targeted interventions and policies that address structural barriers in healthcare access, improve equitable distribution of the neurosurgery workforce, and ensure timely and comprehensive GBM care to all populations.
- Published
- 2023
- Full Text
- View/download PDF
22. A pragmatic clinical trial assessing the effect of a targeted notification and clinical support pathway on the diagnostic evaluation and treatment of individuals with left ventricular hypertrophy (NOTIFY-LVH).
- Author
-
Berman AN, Ginder C, Wang XS, Borden L, Hidrue MK, Searl Como JM, Daly D, Sun YP, Curry WT, Del Carmen M, Morrow DA, Scirica B, Choudhry NK, Januzzi JL, and Wasfy JH
- Abstract
Background: Electronic health records contain vast amounts of cardiovascular data, including potential clues suggesting unrecognized conditions. One important example is the identification of left ventricular hypertrophy (LVH) on echocardiography. If the underlying causes are untreated, individuals are at increased risk of developing clinically significant pathology. As the most common cause of LVH, hypertension accounts for more cardiovascular deaths than any other modifiable risk factor. Contemporary healthcare systems have suboptimal mechanisms for detecting and effectively implementing hypertension treatment before downstream consequences develop. Thus, there is an urgent need to validate alternative intervention strategies for individuals with preexisting-but potentially unrecognized-LVH., Methods: Through a randomized pragmatic trial within a large integrated healthcare system, we will study the impact of a centralized clinical support pathway on the diagnosis and treatment of hypertension and other LVH-associated diseases in individuals with echocardiographic evidence of concentric LVH. Approximately 600 individuals who are not treated for hypertension and who do not have a known cardiomyopathy will be randomized. The intervention will be directed by population health coordinators who will notify longitudinal clinicians and offer to assist with the diagnostic evaluation of LVH. Our hypothesis is that an intervention that alerts clinicians to the presence of LVH will increase the detection and treatment of hypertension and the diagnosis of alternative causes of thickened myocardium. The primary outcome is the initiation of an antihypertensive medication. Secondary outcomes include new hypertension diagnoses and new cardiomyopathy diagnoses. The trial began in March 2023 and outcomes will be assessed 12 months from the start of follow-up., Conclusion: The NOTIFY-LVH trial will assess the efficacy of a centralized intervention to improve the detection and treatment of hypertension and LVH-associated diseases. Additionally, it will serve as a proof-of-concept for how to effectively utilize previously collected electronic health data to improve the recognition and management of a broad range of chronic cardiovascular conditions., Trial Registration: NCT05713916., Competing Interests: Disclosures None reported., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
23. Patterns in Physician Burnout in a Stable-Linked Cohort.
- Author
-
Ortega MV, Hidrue MK, Lehrhoff SR, Ellis DB, Sisodia RC, Curry WT, Del Carmen MG, and Wasfy JH
- Subjects
- Humans, Male, Female, Job Satisfaction, Massachusetts, Population Groups, Physicians, Burnout, Professional epidemiology
- Abstract
Importance: Physician burnout is widely reported to be an increasing problem in the US. Although prior analyses suggest physician burnout is rising nationally, these analyses have substantial limitations, including different physicians joining and leaving clinical practice., Objective: To examine the prevalence of burnout among physicians in a large multispecialty group over a 5-year period., Design, Setting, and Participants: This survey study was conducted in 2017, 2019, and 2021 and involved physician faculty members of the Massachusetts General Physicians Organization. Participants represented different clinical specialties and a full range of career stages. The online survey instrument had 4 domains: physician career and compensation satisfaction, physician well-being, administrative workload on physicians, and leadership and diversity., Exposure: Time., Main Outcomes and Measures: Physician burnout, which was assessed with the Maslach Burnout Inventory. A binary burnout measure was used, which defined burnout as a high score in 2 of the 3 burnout subscales: Exhaustion, Cynicism, and Reduced Personal Efficacy., Results: A total of 1373 physicians (72.9% of the original 2017 cohort) participated in all 3 surveys. The cohort included 690 (50.3%) male, 921 (67.1%) White, and 1189 (86.6%) non-Hispanic individuals. The response rates were 93.0% in 2017, 93.0% in 2019, and 92.0% in 2021. Concerning years of experience, the cohort was relatively well distributed, with the highest number and proportion of physicians (478 [34.8%]) reporting between 11 and 20 years of experience. Within this group, burnout declined from 44.4% (610 physicians) in 2017 to 41.9% (575) in 2019 (P = .18) before increasing to 50.4% (692) in 2021 (P < .001)., Conclusions and Relevance: Findings of this survey study suggest that the physician burnout rate in the US is increasing. This pattern represents a potential threat to the ability of the US health care system to care for patients and needs urgent solutions.
- Published
- 2023
- Full Text
- View/download PDF
24. Bavituximab Decreases Immunosuppressive Myeloid-Derived Suppressor Cells in Newly Diagnosed Glioblastoma Patients.
- Author
-
Ly KI, Richardson LG, Liu M, Muzikansky A, Cardona J, Lou K, Beers AL, Chang K, Brown JM, Ma X, Reardon DA, Arrillaga-Romany IC, Forst DA, Jordan JT, Lee EQ, Dietrich J, Nayak L, Wen PY, Chukwueke U, Giobbie-Hurder A, Choi BD, Batchelor TT, Kalpathy-Cramer J, Curry WT, and Gerstner ER
- Abstract
Purpose: We evaluated the efficacy of bavituximab-a mAb with anti-angiogenic and immunomodulatory properties-in newly diagnosed patients with glioblastoma (GBM) who also received radiotherapy and temozolomide. Perfusion MRI and myeloid-related gene transcription and inflammatory infiltrates in pre-and post-treatment tumor specimens were studied to evaluate on-target effects (NCT03139916)., Patients and Methods: Thirty-three adults with IDH--wild-type GBM received 6 weeks of concurrent chemoradiotherapy, followed by 6 cycles of temozolomide (C1-C6). Bavituximab was given weekly, starting week 1 of chemoradiotherapy, for at least 18 weeks. The primary endpoint was proportion of patients alive at 12 months (OS-12). The null hypothesis would be rejected if OS-12 was ≥72%. Relative cerebral blood flow (rCBF) and vascular permeability (Ktrans) were calculated from perfusion MRIs. Peripheral blood mononuclear cells and tumor tissue were analyzed pre-treatment and at disease progression using RNA transcriptomics and multispectral immunofluorescence for myeloid-derived suppressor cells (MDSC) and macrophages., Results: The study met its primary endpoint with an OS-12 of 73% (95% confidence interval, 59%-90%). Decreased pre-C1 rCBF (HR, 4.63; P = 0.029) and increased pre-C1 Ktrans were associated with improved overall survival (HR, 0.09; P = 0.005). Pre-treatment overexpression of myeloid-related genes in tumor tissue was associated with longer survival. Post-treatment tumor specimens contained fewer immunosuppressive MDSCs (P = 0.01)., Conclusions: Bavituximab has activity in newly diagnosed GBM and resulted in on-target depletion of intratumoral immunosuppressive MDSCs. Elevated pre-treatment expression of myeloid-related transcripts in GBM may predict response to bavituximab., (©2023 American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
25. BRAF-MEK Inhibition in Newly Diagnosed Papillary Craniopharyngiomas.
- Author
-
Brastianos PK, Twohy E, Geyer S, Gerstner ER, Kaufmann TJ, Tabrizi S, Kabat B, Thierauf J, Ruff MW, Bota DA, Reardon DA, Cohen AL, De La Fuente MI, Lesser GJ, Campian J, Agarwalla PK, Kumthekar P, Mann B, Vora S, Knopp M, Iafrate AJ, Curry WT Jr, Cahill DP, Shih HA, Brown PD, Santagata S, Barker FG 2nd, and Galanis E
- Subjects
- Humans, Disease Progression, Mitogen-Activated Protein Kinase Kinases antagonists & inhibitors, Mitogen-Activated Protein Kinase Kinases genetics, Proto-Oncogene Proteins B-raf antagonists & inhibitors, Proto-Oncogene Proteins B-raf genetics, Vemurafenib adverse effects, Vemurafenib therapeutic use, Remission Induction, Craniopharyngioma drug therapy, Craniopharyngioma genetics, Pituitary Neoplasms drug therapy, Pituitary Neoplasms genetics, Antineoplastic Agents adverse effects, Antineoplastic Agents therapeutic use
- Abstract
Background: Craniopharyngiomas, primary brain tumors of the pituitary-hypothalamic axis, can cause clinically significant sequelae. Treatment with the use of surgery, radiation, or both is often associated with substantial morbidity related to vision loss, neuroendocrine dysfunction, and memory loss. Genotyping has shown that more than 90% of papillary craniopharyngiomas carry BRAF V600E mutations, but data are lacking with regard to the safety and efficacy of BRAF-MEK inhibition in patients with papillary craniopharyngiomas who have not undergone previous radiation therapy., Methods: Eligible patients who had papillary craniopharyngiomas that tested positive for BRAF mutations, had not undergone radiation therapy previously, and had measurable disease received the BRAF-MEK inhibitor combination vemurafenib-cobimetinib in 28-day cycles. The primary end point of this single-group, phase 2 study was objective response at 4 months as determined with the use of centrally determined volumetric data., Results: Of the 16 patients in the study, 15 (94%; 95% confidence interval [CI], 70 to 100) had a durable objective partial response or better to therapy. The median reduction in the volume of the tumor was 91% (range, 68 to 99). The median follow-up was 22 months (95% CI, 19 to 30) and the median number of treatment cycles was 8. Progression-free survival was 87% (95% CI, 57 to 98) at 12 months and 58% (95% CI, 10 to 89) at 24 months. Three patients had disease progression during follow-up after therapy had been discontinued; none have died. The sole patient who did not have a response stopped treatment after 8 days owing to toxic effects. Grade 3 adverse events that were at least possibly related to treatment occurred in 12 patients, including rash in 6 patients. In 2 patients, grade 4 adverse events (hyperglycemia in 1 patient and increased creatine kinase levels in 1 patient) were reported; 3 patients discontinued treatment owing to adverse events., Conclusions: In this small, single-group study involving patients with papillary craniopharyngiomas, 15 of 16 patients had a partial response or better to the BRAF-MEK inhibitor combination vemurafenib-cobimetinib. (Funded by the National Cancer Institute and others; ClinicalTrials.gov number, NCT03224767.)., (Copyright © 2023 Massachusetts Medical Society.)
- Published
- 2023
- Full Text
- View/download PDF
26. Molecular Evidence for Olfactory Neuroblastoma as a Tumor of Malignant Globose Basal Cells.
- Author
-
Zunitch MJ, Fisch AS, Lin B, Barrios-Camacho CM, Faquin WC, Tachie-Baffour Y, Louie JD, Jang W, Curry WT, Gray ST, Lin DT, Schwob JE, and Holbrook EH
- Subjects
- Humans, Mice, Animals, Neurons pathology, Nasal Cavity metabolism, Nasal Cavity pathology, Esthesioneuroblastoma, Olfactory diagnosis, Esthesioneuroblastoma, Olfactory metabolism, Esthesioneuroblastoma, Olfactory pathology, Paranasal Sinus Neoplasms pathology, Nose Neoplasms genetics, Nose Neoplasms diagnosis
- Abstract
Olfactory neuroblastoma (ONB, esthesioneuroblastoma) is a sinonasal cancer with an underdeveloped diagnostic toolkit, and is the subject of many incidents of tumor misclassification throughout the literature. Despite its name, connections between the cancer and normal cells of the olfactory epithelium have not been systematically explored and markers of olfactory epithelial cell types are not deployed in clinical practice. Here, we utilize an integrated human-mouse single-cell atlas of the nasal mucosa, including the olfactory epithelium, to identify transcriptomic programs that link ONB to a specific population of stem/progenitor cells known as olfactory epithelial globose basal cells (GBCs). Expression of a GBC transcription factor NEUROD1 distinguishes both low- and high-grade ONB from sinonasal undifferentiated carcinoma, a potential histologic mimic with a distinctly unfavorable prognosis. Furthermore, we identify a reproducible subpopulation of highly proliferative ONB cells expressing the GBC stemness marker EZH2, suggesting that EZH2 inhibition may play a role in the targeted treatment of ONB. Finally, we study the cellular states comprising ONB parenchyma using single-cell transcriptomics and identify evidence of a conserved GBC transcriptional regulatory circuit that governs divergent neuronal-versus-sustentacular differentiation. These results link ONB to a specific cell type for the first time and identify conserved developmental pathways within ONB that inform diagnostic, prognostic, and mechanistic investigation., (Copyright © 2023 United States & Canadian Academy of Pathology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
27. Phase IIa Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma.
- Author
-
Ahluwalia MS, Reardon DA, Abad AP, Curry WT, Wong ET, Figel SA, Mechtler LL, Peereboom DM, Hutson AD, Withers HG, Liu S, Belal AN, Qiu J, Mogensen KM, Dharma SS, Dhawan A, Birkemeier MT, Casucci DM, Ciesielski MJ, and Fenstermaker RA
- Subjects
- Male, Humans, Female, Young Adult, Adult, Middle Aged, Aged, Aged, 80 and over, Temozolomide therapeutic use, Survivin therapeutic use, Antineoplastic Agents, Alkylating therapeutic use, Adjuvants, Immunologic therapeutic use, Vaccines, Subunit therapeutic use, Glioblastoma drug therapy, Brain Neoplasms drug therapy
- Abstract
Purpose: Despite intensive treatment with surgery, radiation therapy, temozolomide (TMZ) chemotherapy, and tumor-treating fields, mortality of newly diagnosed glioblastoma (nGBM) remains very high. SurVaxM is a peptide vaccine conjugate that has been shown to activate the immune system against its target molecule survivin, which is highly expressed by glioblastoma cells. We conducted a phase IIa, open-label, multicenter trial evaluating the safety, immunologic effects, and survival of patients with nGBM receiving SurVaxM plus adjuvant TMZ following surgery and chemoradiation (ClinicalTrials.gov identifier: NCT02455557)., Methods: Sixty-four patients with resected nGBM were enrolled including 38 men and 26 women, in the age range of 20-82 years. Following craniotomy and fractionated radiation therapy with concurrent TMZ, patients received four doses of SurVaxM (500 μg once every 2 weeks) in Montanide ISA-51 plus sargramostim (granulocyte macrophage colony-stimulating factor) subcutaneously. Patients subsequently received adjuvant TMZ and maintenance SurVaxM concurrently until progression. Progression-free survival (PFS) and overall survival (OS) were reported. Immunologic responses to SurVaxM were assessed., Results: SurVaxM plus TMZ was well tolerated with no serious adverse events attributable to SurVaxM. Of the 63 patients who were evaluable for outcome, 60 (95.2%) remained progression-free 6 months after diagnosis (prespecified primary end point). Median PFS was 11.4 months and median OS was 25.9 months measured from first dose of SurVaxM. SurVaxM produced survivin-specific CD8+ T cells and antibody/immunoglobulin G titers. Apparent clinical benefit of SurVaxM was observed in both methylated and unmethylated patients., Conclusion: SurVaxM appeared to be safe and well tolerated. The combination represents a promising therapy for nGBM. For patients with nGBM treated in this manner, PFS may be an acceptable surrogate for OS. A large randomized clinical trial of SurVaxM for nGBM is in progress.
- Published
- 2023
- Full Text
- View/download PDF
28. Tandem chimeric antigen receptor (CAR) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma.
- Author
-
Schmidts A, Srivastava AA, Ramapriyan R, Bailey SR, Bouffard AA, Cahill DP, Carter BS, Curry WT, Dunn GP, Frigault MJ, Gerstner ER, Ghannam JY, Kann MC, Larson RC, Leick MB, Nahed BV, Richardson LG, Scarfò I, Sun J, Wakimoto H, Maus MV, and Choi BD
- Abstract
Background: Chimeric antigen receptor (CAR) T cells have achieved remarkable responses in patients with hematological malignancies; however, the potential of this therapeutic platform for solid tumors like glioblastoma (GBM) has been limited, due in large part to the targeting of single antigens in a heterogeneous disease. Strategies that allow CAR T cells to engage multiple antigens concomitantly may broaden therapeutic responses and mitigate the effects of immune escape., Methods: Here we have developed a novel, dual-specific, tandem CAR T (TanCART) cell with the ability to simultaneously target both EGFRvIII and IL-13Rα2, two well-characterized tumor antigens that are frequently found on the surface of GBM cells but completely absent from normal brain tissues. We employed both standard immunological assays and multiple orthotopic preclinical models including patient-derived xenograft to demonstrate efficacy of this approach against heterogeneous tumors., Results: Tandem CAR T cells displayed enhanced cytotoxicity in vitro against heterogeneous GBM populations, including patient-derived brain tumor cultures ( P < .05). Compared to CAR T cells targeting single antigens, dual antigen engagement through the tandem construct was necessary to achieve long-term, complete, and durable responses in orthotopic murine models of heterogeneous GBM, including patient-derived xenografts ( P < .05)., Conclusions: We demonstrate that TanCART is effective against heterogeneous tumors in the brain. These data lend further credence to the development of multi-specific CAR T cells in the treatment of GBM and other cancers., (© The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.)
- Published
- 2022
- Full Text
- View/download PDF
29. Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: A contemporary single-institution experience.
- Author
-
Saraf A, Yock TI, Niemierko A, Oh KS, Curry WT, Butler WE, Forst DA, Arrillaga-Romany I, Ebb DH, Tarbell NJ, MacDonald S, Loeffler JS, and Shih HA
- Subjects
- Adult, Humans, Adolescent, Young Adult, Middle Aged, Retrospective Studies, Combined Modality Therapy, Disease-Free Survival, Medulloblastoma pathology, Cerebellar Neoplasms pathology, Craniospinal Irradiation
- Abstract
Background: Medulloblastoma (MB) is a rare central nervous system malignancy of adults, with limited contemporary studies to define treatment guidelines and expected late toxicity., Methods: A single-center, retrospective study was conducted of patients age ≥18 years from 1997-2019 with MB and who were treated with postoperative radiotherapy. Late toxicity was defined as a minimum of 18 months from diagnosis. Overall survival (OS) and progression-free survival (PFS) were characterized using Kaplan-Meier and Cox regression analyses., Results: Fifty-nine patients met criteria, with median age of 25 years (range 18-62 y) and median follow-up of 6.5 years (range 0.7-23.1 y). At diagnosis, 68% were standard-risk, 88% Chang M0, and 22% with anaplastic histology. Gross total resection was achieved in 75%; median craniospinal irradiation dose was 30.6 Gy (relative biological effectiveness [RBE]), median total dose was 54.0 Gy (RBE), 80% received proton radiotherapy; 81% received chemotherapy. 5 year PFS and OS were 86.5% and 95.8%, respectively; 10 year PFS and OS were 83.9% and 90.7%, respectively. Anaplastic histology was associated with worse PFS (P = .04). Among eight recurrences, 25% presented after 5 years. Most common grade ≥2 late toxicities were anxiety/depressive symptoms (30%), motor dysfunction (25%), and ototoxicity (22%). Higher posterior fossa radiation dose was associated with increased risk of late toxicity, including worse cognitive dysfunction (P = .05)., Conclusions: Adults with MB have favorable survival outcomes, but late failures and toxicity are not uncommon. Better understanding of prognostic factors, possibly from molecular subtyping, may help to define more personalized treatments for patients with high risk of recurrence and long-term treatment sequelae., (© The Author(s) 2022. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
30. Magnetic resonance spectroscopy outperforms perfusion in distinguishing between pseudoprogression and disease progression in patients with glioblastoma.
- Author
-
El-Abtah ME, Talati P, Fu M, Chun B, Clark P, Peters A, Ranasinghe A, He J, Rapalino O, Batchelor TT, Gilberto Gonzalez R, Curry WT, Dietrich J, Gerstner ER, and Ratai EM
- Abstract
Background: There is a need to establish biomarkers that distinguish between pseudoprogression (PsP) and true tumor progression in patients with glioblastoma (GBM) treated with chemoradiation., Methods: We analyzed magnetic resonance spectroscopic imaging (MRSI) and dynamic susceptibility contrast (DSC) MR perfusion data in patients with GBM with PsP or disease progression after chemoradiation. MRSI metabolites of interest included intratumoral choline (Cho), myo-inositol (mI), glutamate + glutamine (Glx), lactate (Lac), and creatine on the contralateral hemisphere (c-Cr). Student T -tests and area under the ROC curve analyses were used to detect group differences in metabolic ratios and their ability to predict clinical status, respectively., Results: 28 subjects (63 ± 9 years, 19 men) were evaluated. Subjects with true progression ( n = 20) had decreased enhancing region mI/c-Cr ( P = .011), a marker for more aggressive tumors, compared to those with PsP, which predicted tumor progression (AUC: 0.84 [0.76, 0.92]). Those with true progression had elevated Lac/Glx ( P = .0009), a proxy of the Warburg effect, compared to those with PsP which predicted tumor progression (AUC: 0.84 [0.75, 0.92]). Cho/c-Cr did not distinguish between PsP and true tumor progression. Despite rCBV (AUC: 0.70 [0.60, 0.80]) and rCBF (AUC: 0.75 [0.65, 0.84]) being individually predictive of tumor response, they added no additional predictive value when combined with MRSI metabolic markers., Conclusions: Incorporating enhancing lesion MRSI measures of mI/c-Cr and Lac/Glx into brain tumor imaging protocols can distinguish between PsP and true progression and inform patient management decisions., (© The Author(s) 2022. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology.)
- Published
- 2022
- Full Text
- View/download PDF
31. Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition.
- Author
-
Alvarez-Breckenridge C, Markson SC, Stocking JH, Nayyar N, Lastrapes M, Strickland MR, Kim AE, de Sauvage M, Dahal A, Larson JM, Mora JL, Navia AW, Klein RH, Kuter BM, Gill CM, Bertalan M, Shaw B, Kaplan A, Subramanian M, Jain A, Kumar S, Danish H, White M, Shahid O, Pauken KE, Miller BC, Frederick DT, Hebert C, Shaw M, Martinez-Lage M, Frosch M, Wang N, Gerstner E, Nahed BV, Curry WT, Carter B, Cahill DP, Boland GM, Izar B, Davies MA, Sharpe AH, Suvà ML, Sullivan RJ, Brastianos PK, and Carter SL
- Subjects
- Humans, Immune Checkpoint Inhibitors, Tumor Microenvironment, Brain Neoplasms, Melanoma
- Abstract
Melanoma-derived brain metastases (MBM) represent an unmet clinical need because central nervous system progression is frequently an end stage of the disease. Immune checkpoint inhibitors (ICI) provide a clinical opportunity against MBM; however, the MBM tumor microenvironment (TME) has not been fully elucidated in the context of ICI. To dissect unique elements of the MBM TME and correlates of MBM response to ICI, we collected 32 fresh MBM and performed single-cell RNA sequencing of the MBM TME and T-cell receptor clonotyping on T cells from MBM and matched blood and extracranial lesions. We observed myeloid phenotypic heterogeneity in the MBM TME, most notably multiple distinct neutrophil states, including an IL8-expressing population that correlated with malignant cell epithelial-to-mesenchymal transition. In addition, we observed significant relationships between intracranial T-cell phenotypes and the distribution of T-cell clonotypes intracranially and peripherally. We found that the phenotype, clonotype, and overall number of MBM-infiltrating T cells were associated with response to ICI, suggesting that ICI-responsive MBMs interact with peripheral blood in a manner similar to extracranial lesions. These data identify unique features of the MBM TME that may represent potential targets to improve clinical outcomes for patients with MBM., (©2022 American Association for Cancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
32. The New England Neurosurgical Society: growth and evolution over 70 years.
- Author
-
Wang AY, Sharma V, Bi WL, Curry WT, Florman JE, Groff MW, Heilman CB, Hong J, Kryzanski J, Lollis SS, McGillicuddy GT, Moliterno J, Ogilvy CS, Oh DS, Oyelese AA, Proctor MR, Shear PA, Wakefield AE, Whitmore RG, and Riesenburger RI
- Subjects
- Humans, Leadership, Neurosurgeons, New England, Referral and Consultation, History, 20th Century, History, 21st Century, Neurosurgery history, Societies, Medical history, Societies, Medical organization & administration
- Abstract
The New England Neurosurgical Society (NENS) was founded in 1951 under the leadership of its first President (Dr. William Beecher Scoville) and Secretary-Treasurer (Dr. Henry Thomas Ballantine). The purpose of creating the NENS was to unite local neurosurgeons in the New England area; it was one of the first regional neurosurgical societies in America. Although regional neurosurgical societies are important supplements to national organizations, they have often been overshadowed in the available literature. Now in its 70th year, the NENS continues to serve as a platform to represent the needs of New England neurosurgeons, foster connections and networks with colleagues, and provide research and educational opportunities for trainees. Additionally, regional societies enable discussion of issues uniquely relevant to the region, improve referral patterns, and allow for easier attendance with geographic proximity. In this paper, the authors describe the history of the NENS and provide a roadmap for its future. The first section portrays the founders who led the first meetings and establishment of the NENS. The second section describes the early years of the NENS and profiles key leaders. The third section discusses subsequent neurosurgeons who steered the NENS and partnerships with other societies. In the fourth section, the modern era of the NENS and its current activities are highlighted.
- Published
- 2022
- Full Text
- View/download PDF
33. Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas.
- Author
-
Brastianos PK, Kim AE, Giobbie-Hurder A, Lee EQ, Wang N, Eichler AF, Chukwueke U, Forst DA, Arrillaga-Romany IC, Dietrich J, Corbin Z, Moliterno J, Baehring J, White M, Lou KW, Larson J, de Sauvage MA, Evancic K, Mora J, Nayyar N, Loeffler J, Oh K, Shih HA, Curry WT, Cahill DP, Barker FG, Gerstner ER, and Santagata S
- Subjects
- Antibodies, Monoclonal, Humanized adverse effects, Disease Progression, Humans, Tumor Microenvironment, Meningeal Neoplasms drug therapy, Meningioma drug therapy
- Abstract
High-grade meningiomas are associated with neuro-cognitive morbidity and have limited treatments. High-grade meningiomas harbor an immunosuppressive tumor microenvironment (TME) and programmed death-ligand 1 (PD-L1) expression may contribute to their aggressive phenotype. Here, we present the results of a single-arm, open-label phase 2 trial (NCT03279692) evaluating the efficacy of pembrolizumab, a PD-1 inhibitor, in a cohort of 25 evaluable patients with recurrent and progressive grade 2 and 3 meningiomas. The primary endpoint is the proportion of patients alive and progression-free at 6 months (PFS-6). Secondary endpoints include progression-free and overall survival, best intracranial response, and toxicity. Our study has met its primary endpoint and achieved a PFS-6 rate of 0.48 (90% exact CI: 0.31-0.66) and a median PFS of 7.6 months (90% CI: 3.4-12.9 months). Twenty percent of patients have experienced one (or more) grade-3 or higher treatment-related adverse events. These results suggest that pembrolizumab exerts promising efficacy on a subset of these tumors. Further studies are needed to identify the biological facets within the meningioma TME that may drive response to immune-based therapies., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
34. Implications of IDH mutations on immunotherapeutic strategies for malignant glioma.
- Author
-
Richardson LG, Miller JJ, Kitagawa Y, Wakimoto H, Choi BD, and Curry WT
- Subjects
- Humans, Immunotherapy, Isocitrate Dehydrogenase genetics, Mutation genetics, Tumor Microenvironment, Brain Neoplasms genetics, Brain Neoplasms metabolism, Brain Neoplasms therapy, Glioma genetics, Glioma therapy
- Abstract
Immunotherapy has emerged as a promising approach for treating aggressive solid tumors, even within the CNS. Mutation in the metabolic gene isocitrate dehydrogenase 1 (IDH1) represents not only a major glioma defining biomarker but also an attractive therapeutic neoantigen. As patients with IDH-mutant glioma enter early-phase vaccine and immune checkpoint inhibitor clinical trials, there is emerging evidence that implicates the oncometabolite, 2-hydroxyglutarate (2HG), generated by the neomorphic activity of mutant IDH, as a potential barrier to current immunotherapeutic approaches. Here, the authors review the immunomodulatory and immunosuppressive roles of 2HG within the unique IDH-mutant glioma tumor immune microenvironment and discuss promising immunotherapeutic approaches currently being investigated in preclinical models.
- Published
- 2022
- Full Text
- View/download PDF
35. A rapid genotyping panel for detection of primary central nervous system lymphoma.
- Author
-
Gupta M, Burns EJ, Georgantas NZ, Thierauf J, Nayyar N, Gordon A, Jones SS, Pisapia M, Sun Y, Burns RP, Velarde J, Jordan JT, Frigault MJ, Nahed BV, Jones PS, Barker FG, Curry WT, Gupta R, Batchelor TT, Romero JM, Brastianos PK, Marble HD, Martinez-Lage M, Tateishi K, Lennerz JK, Dietrich J, Cahill DP, Carter BS, and Shankar GM
- Subjects
- Adult, Female, Humans, Central Nervous System Neoplasms cerebrospinal fluid, Central Nervous System Neoplasms diagnosis, Central Nervous System Neoplasms genetics, Genotyping Techniques, Lymphoma, Non-Hodgkin cerebrospinal fluid, Lymphoma, Non-Hodgkin diagnosis, Lymphoma, Non-Hodgkin genetics, Mutation, Neoplasm Proteins cerebrospinal fluid, Neoplasm Proteins genetics, Real-Time Polymerase Chain Reaction
- Abstract
Diagnosing primary central nervous system lymphoma (PCNSL) frequently requires neurosurgical biopsy due to nonspecific radiologic features and the low yield of cerebrospinal fluid (CSF) studies. We characterized the clinical evaluation of suspected PCNSL (N = 1007 patients) and designed a rapid multiplexed genotyping assay for MYD88, TERT promoter, IDH1/2, H3F3A, and BRAF mutations to facilitate the diagnosis of PCNSL from CSF and detect other neoplasms in the differential diagnosis. Among 159 patients with confirmed PCNSL, the median time to secure a diagnosis of PCNSL was 10 days, with a range of 0 to 617 days. Permanent histopathology confirmed PCNSL in 142 of 152 biopsies (93.4%), whereas CSF analyses were diagnostic in only 15/113 samplings (13.3%). Among 86 archived clinical specimens, our targeted genotyping assay accurately detected hematologic malignancies with 57.6% sensitivity and 100% specificity (95% confidence interval [CI]: 44.1% to 70.4% and 87.2% to 100%, respectively). MYD88 and TERT promoter mutations were prospectively identified in DNA extracts of CSF obtained from patients with PCNSL and glioblastoma, respectively, within 80 minutes. Across 132 specimens, hallmark mutations indicating the presence of malignancy were detected with 65.8% sensitivity and 100% specificity (95% CI: 56.2%-74.5% and 83.9%-100%, respectively). This targeted genotyping approach offers a rapid, scalable adjunct to reduce diagnostic and treatment delays in PCNSL., (© 2021 by The American Society of Hematology.)
- Published
- 2021
- Full Text
- View/download PDF
36. Intraoperative thalamocortical tract monitoring via direct cortical recordings during craniotomy.
- Author
-
Simon MV, Curry WT, Jones PS, Cahill DP, Carter BS, Rapalino O, Malik AN, and Nahed BV
- Subjects
- Adult, Aged, Aged, 80 and over, Brain Neoplasms physiopathology, Electrocorticography methods, Feasibility Studies, Female, Humans, Male, Middle Aged, Retrospective Studies, Brain Neoplasms surgery, Craniotomy methods, Evoked Potentials, Somatosensory physiology, Intraoperative Neurophysiological Monitoring methods, Motor Cortex physiology, Thalamus physiology
- Abstract
Objective: Neuromonitoring of primary motor regions allows preservation of motor strength and is frequently employed during cranial procedures. Less is known about protection of sensory function and ability to modulate movements, both of which rely on integrity of thalamocortical afferents (TCA) to fronto-parietal regions. We describe our experience with TCA monitoring and their cortical relays during brain tumor surgery., Methodology: To study its feasibility and usefulness, continuous somatosensory evoked potentials (SSEP) recording via a subdural electrode was attempted in 32 consecutive patients., Results: Median and posterior tibial SSEP were successfully monitored in 31 and 17 patients respectively. SSEP improved lesion localization and prevented unnecessary cortical stimulation in 9 and 16 cases respectively. A threshold of ≥30% SSEP amplitude decrease influenced management in 10 patients while a decrement of ≥50 % had a sensitivity of 0.89 and specificity of 1 in detecting worsening of sensory function. Simultaneous motor evoked potentials (MEP) and SSEP monitoring were performed in 10 cases, 9 of which showed short-lived fluctuations of the former., Conclusion: Direct cortical SSEP monitoring is feasible, informs management and predicts outcome., Significance: Early intervention prevents sensory deficit. Concomitant MEP fluctuations may reflect modulation of motor activity by TCA., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2021 International Federation of Clinical Neurophysiology. Published by Elsevier B.V. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
37. Commentary: Chimeric Antigen Receptor T-Cell Therapy: Updates in Glioblastoma Treatment.
- Author
-
Yu X, Curry WT, Gerstner ER, Cahill DP, Nahed BV, Maus MV, Carter BS, and Choi BD
- Subjects
- Cell- and Tissue-Based Therapy, Humans, Immunotherapy, Adoptive, Brain Neoplasms therapy, Glioblastoma therapy, Receptors, Chimeric Antigen
- Published
- 2021
- Full Text
- View/download PDF
38. Craniopharyngiomas, including Recurrent Cases, Lack TERT Promoter Hotspot Mutations.
- Author
-
Fujio S, Juratli TA, Takajo T, Arita K, Nagano Y, Yoshimoto K, Nayyar N, Curry WT Jr, Martinez-Lage M, Cahill DP, Barker FG 2nd, and Brastianos PK
- Subjects
- Humans, Mutation, Neoplasm Recurrence, Local genetics, Promoter Regions, Genetic genetics, Craniopharyngioma genetics, Pituitary Neoplasms genetics, Telomerase genetics
- Abstract
Adamantinomatous craniopharyngiomas (ACP) are characterized by alterations in the CTNNB1 gene while almost all papillary craniopharyngiomas (PCP) harbor a canonical V600E mutation in the BRAF gene. Although other recurrent driver genes have not been described to date in craniopharyngiomas, the heterogeneous clinical course of these tumors might be associated with the acquisition of further genomic alterations. It is well known that telomerase reverse transcriptase (TERT) promoter (TERTp) alterations, including mutations or methylation, upregulate the expression of TERT and increase telomerase activity, promoting tumorigenesis. We investigated whether TERTp mutations or methylation are associated with tumor relapse in a subset of craniopharyngiomas. Samples from 42 patients with histologically confirmed craniopharyngioma were retrieved. We determined TERTp, BRAF, and CTNNB1 hotspot mutations in all samples using targeted sequencing and the TERTp methylation status by methylation-specific polymerase chain reaction (PCR) in 30 samples. While BRAF V600E mutations and CTNNB1 mutations were detected in 12 (28.6%) and 21 patients (50%) in the initial tumors and subsequent recurrences, respectively, none of the patients in our cohort, including those with multiple relapses, harbored a TERTp mutation. Furthermore, TERTp methylation was detected in 14 out of 24 cases (58.3%) with available primary samples; however, no correlation between TERTp methylation with the pathological subtype, genotype, or tumor aggressiveness was detected. These data suggest that elevated telomerase activity via acquisition of TERTp mutations is an infrequent pathway in the tumorigenesis of craniopharyngiomas, regardless of their clinical course.
- Published
- 2021
- Full Text
- View/download PDF
39. Microsurgical resection of foramen magnum meningioma: multi-institutional retrospective case series and proposed surgical risk scoring system.
- Author
-
Fatima N, Shin JH, Curry WT, Chang SD, and Meola A
- Subjects
- Female, Foramen Magnum diagnostic imaging, Foramen Magnum surgery, Humans, Male, Postoperative Complications epidemiology, Retrospective Studies, Risk Factors, Meningeal Neoplasms diagnostic imaging, Meningeal Neoplasms surgery, Meningioma diagnostic imaging, Meningioma surgery, Skull Base Neoplasms
- Abstract
Purpose: Foramen magnum meningiomas (FMMs) are a major surgical challenge, due to relevant surgical morbidity and mortality. The paper aims to review the clinical (symptomatic improvement, complication rate, length of hospital stay) and radiological outcome (completeness of resection) of microsurgical resection of FMMs, and to identify predictors of complications., Methods: A multi-institutional retrospective review of prospectively maintained database of FMMs included 51 patients (74.5% females) with a median tumor volume of 8.18 cm
3 (range, 1.77-57.9 cm3 ) and median follow-up of 36 months (range, 0.30-180.0 months). Tumors were resected though suboccipital approach (58.8%) or posterior-lateral approaches (39.3%), including far-lateral, extreme lateral and transcondylar approaches., Results: Gross-total resection (GTR) was achieved in 80.4% and 98% of cases did not present tumor regrowth or recurrence. Clinical symptoms improved in 34 patients (66.7%) and worsened in 5 (9.8%). The median length of hospital stay was 5 days. Mortality was null. Postoperative complications developed in 15 patients (29.4%), with cerebrospinal fluid leak (7.8%) and lower cranial nerves deficits (7.8%) as the most frequent. Craniospinal location (p = 0.03), location anterior to the dentate ligament (DL) (p = 0.02), involvement of vertebral artery (VA) (p = 0.03) were significantly associated with complication rate. These three elements allow calculating the Foramen Magnum Meningioma Risk Score (FRMMRS), to estimate the risk of post-operative complications., Conclusion: Microsurgical resection allows for high GTR rate and low rate of tumor regrowth or recurrence, despite complications in one third of the patients. The FMMRS allows classifying FMMs and estimating the risk of post-operative complications.- Published
- 2021
- Full Text
- View/download PDF
40. Endonasal CNS Delivery System for Blood-Brain Barrier Impermeant Therapeutic Oligonucleotides Using Heterotopic Mucosal Engrafting.
- Author
-
Pawar G, Parayath NN, Sharma AA, Coito C, Khorkova O, Hsiao J, Curry WT, Amiji MM, and Bleier BS
- Abstract
The most significant obstacle in the treatment of neurological disorders is the blood-brain barrier (BBB), which prevents 98% of all potential neuropharmaceuticals from reaching the central nervous system (CNS). Brain derived neurotrophic factor (BDNF) is one of the most intensely studied targets in Parkinson's disease (PD) as it can reverse disease progression. BDNF AntagoNAT's (ATs) are synthetic oligonucleotide-like compounds capable of upregulating endogenous BDNF expression. Despite the significant promise of BDNF AT therapies for PD, they cannot cross the blood-brain barrier (BBB). Our group has developed an innovative endonasal heterotopic mucosal grafting technique to provide a permanent method of permeabilizing the BBB. This method is based on established endoscopic surgical procedures currently used in routine clinical practice. Our overall goal for the study was to investigate the distribution and efficacy of BDNF AT's using an extra-cranial graft model in naïve rats using the innovative heterotopic mucosal engrafting technique. BDNF AT cationic liposomes (ideal size range 200-250 nm) were developed and characterized to enhance the delivery to rat brain. Uptake, distribution and transfection efficiency of BDNF AntagoNAT's in saline and liposomes were evaluated qualitatively (microscopy) and quantitatively (ELISA and AT hybridization assays) in RT4-D6P2T rat schwannoma cells and in naïve rats. In vivo therapeutic efficacy of BDNF AT's encapsulated in liposomes was evaluated in a 6-OHDA toxin model of PD using western blot and tyrosine hydroxylase immunohistochemistry. Using complimentary in vitro and in vivo techniques, our results demonstrate that grafts are capable of delivering therapeutic levels of BDNF ATs in liposomes and saline formulation throughout the brain resulting in significant BDNF upregulation in key end target regions relevant to PD. BDNF AT liposomes resulted in a better distribution in rat brain as compared to saline control. The delivered BDNF AT's encapsulated in liposomes also conferred a neuroprotective effect in a rat 6-OHDA model of PD. As a platform technique, these results further suggest that this approach may be utilized to deliver other BBB impermeant oligonucleotide-based therapeutics thereby opening the door to additional treatment options for CNS disease., Competing Interests: CC, OK and JH were employed by OPKO Health Inc. BB holds a patent assigned to Massachusetts Eye and Ear covering transmucosal delivery methods to the central nervous system. BB has consultant relationships with Inquis Medical, Olympus, Medtronic, Karl Storz, Sinopsys, Baxter, and 3D Matrix and receives royalties from Theime. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Pawar, Parayath, Sharma, Coito, Khorkova, Hsiao, Curry, Amiji and Bleier.)
- Published
- 2021
- Full Text
- View/download PDF
41. Case 10-2021: A 70-Year-Old Man with Depressed Mood, Unsteady Gait, and Urinary Incontinence.
- Author
-
Marouf F, Glover M, Wininger B, and Curry WT
- Subjects
- Aged, Bipolar Disorder complications, Bipolar Disorder drug therapy, Cerebral Ventricles pathology, Depression etiology, Diagnosis, Differential, Humans, Hydrocephalus, Normal Pressure complications, Hydrocephalus, Normal Pressure surgery, Magnetic Resonance Imaging, Male, Urinary Incontinence etiology, Cerebral Ventricles diagnostic imaging, Gait Disorders, Neurologic etiology, Hydrocephalus, Normal Pressure diagnosis
- Published
- 2021
- Full Text
- View/download PDF
42. Commentary: The Glioma-Network Interface: A Review of the Relationship Between Glioma Molecular Subtype and Intratumoral Function.
- Author
-
Choi BD, Grannan BL, Cahill DP, and Curry WT
- Subjects
- Humans, Brain Neoplasms, Glioma
- Published
- 2021
- Full Text
- View/download PDF
43. Neurophysiologic Mapping of Thalamocortical Tract in Asleep Craniotomies: Promising Results From an Early Experience.
- Author
-
Simon MV, Lee DK, Choi BD, Talati PA, Yang JC, Koch MJ, Jones PS, and Curry WT
- Subjects
- Brain Mapping, Craniotomy, Evoked Potentials, Somatosensory, Humans, Evoked Potentials, Motor, Monitoring, Intraoperative
- Abstract
Background: Subcortical mapping of the corticospinal tract has been extensively used during craniotomies under general anesthesia to achieve maximal resection while avoiding postoperative motor deficits. To our knowledge, similar methods to map the thalamocortical tract (TCT) have not yet been developed., Objective: To describe a neurophysiologic technique for TCT identification in 2 patients who underwent resection of frontoparietal lesions., Methods: The central sulcus (CS) was identified using the somatosensory evoked potentials (SSEP) phase reversal technique. Furthermore, monitoring of the cortical postcentral N20 and precentral P22 potentials was performed during resection. Subcortical electrical stimulation in the resection cavity was done using the multipulse train (case #1) and Penfield (case #2) techniques., Results: Subcortical stimulation within the postcentral gyrus (case #1) and in depth of the CS (case #2), resulted in a sudden drop in amplitudes in N20 (case #1) and P22 (case #2), respectively. In both patients, the potentials promptly recovered once the stimulation was stopped. These results led to redirection of the surgical plane with avoidance of damage of thalamocortical input to the primary somatosensory (case #1) and motor regions (case #2). At the end of the resection, there were no significant changes in the median SSEP. Both patients had no new long-term postoperative sensory or motor deficit., Conclusion: This method allows identification of TCT in craniotomies under general anesthesia. Such input is essential not only for preservation of sensory function but also for feedback modulation of motor activity., (Copyright © 2020 by the Congress of Neurological Surgeons.)
- Published
- 2021
- Full Text
- View/download PDF
44. TERT Promoter Mutation Analysis for Blood-Based Diagnosis and Monitoring of Gliomas.
- Author
-
Muralidharan K, Yekula A, Small JL, Rosh ZS, Kang KM, Wang L, Lau S, Zhang H, Lee H, Bettegowda C, Chicoine MR, Kalkanis SN, Shankar GM, Nahed BV, Curry WT, Jones PS, Cahill DP, Balaj L, and Carter BS
- Subjects
- Adult, Aged, Brain Neoplasms blood, Brain Neoplasms therapy, Cell Line, Tumor, Cohort Studies, DNA Mutational Analysis methods, Feasibility Studies, Female, Glioma blood, Glioma therapy, Humans, Liquid Biopsy methods, Male, Middle Aged, Mutation, Polymerase Chain Reaction, Promoter Regions, Genetic, Sensitivity and Specificity, Biomarkers, Tumor genetics, Brain Neoplasms diagnosis, Glioma diagnosis, Telomerase genetics
- Abstract
Purpose: Liquid biopsy offers a minimally invasive tool to diagnose and monitor the heterogeneous molecular landscape of tumors over time and therapy. Detection of TERT promoter mutations ( C228T , C250T ) in cfDNA has been successful for some systemic cancers but has yet to be demonstrated in gliomas, despite the high prevalence of these mutations in glioma tissue (>60% of all tumors)., Experimental Design: Here, we developed a novel digital droplet PCR (ddPCR) assay that incorporates features to improve sensitivity and allows for the simultaneous detection and longitudinal monitoring of two TERT promoter mutations ( C228T and C250T ) in cfDNA from the plasma of patients with glioma., Results: In baseline performance in tumor tissue, the assay had perfect concordance with an independently performed clinical pathology laboratory assessment of TERT promoter mutations in the same tumor samples [95% confidence interval (CI), 94%-100%]. Extending to matched plasma samples, we detected TERT mutations in both discovery and blinded multi-institution validation cohorts with an overall sensitivity of 62.5% (95% CI, 52%-73%) and a specificity of 90% (95% CI, 80%-96%) compared with the gold-standard tumor tissue-based detection of TERT mutations. Upon longitudinal monitoring in 5 patients, we report that peripheral TERT -mutant allele frequency reflects the clinical course of the disease, with levels decreasing after surgical intervention and therapy and increasing with tumor progression., Conclusions: Our results demonstrate the feasibility of detecting circulating cfDNA TERT promoter mutations in patients with glioma with clinically relevant sensitivity and specificity., (©2020 American Association for Cancer Research.)
- Published
- 2021
- Full Text
- View/download PDF
45. Adjuvant Radiation Therapy Versus Surveillance After Surgical Resection of Atypical Meningiomas.
- Author
-
Lee G, Lamba N, Niemierko A, Kim DW, Chapman PH, Loeffler JS, Curry WT, Martuza RL, Oh KS, Barker FG 2nd, and Shih HA
- Subjects
- Aged, Female, Humans, Male, Meningioma pathology, Middle Aged, Postoperative Period, Retrospective Studies, Treatment Outcome, Meningioma radiotherapy, Meningioma surgery, Radiotherapy, Adjuvant, Watchful Waiting
- Abstract
Purpose: The optimal timing of adjuvant radiation therapy (RT) in the management of atypical meningiomas remains controversial. We compared the outcomes of atypical meningiomas managed with upfront adjuvant RT versus postoperative surveillance., Methods and Materials: Patients with intracranial atypical meningiomas who underwent resection between 2000 and 2015 at a single institution were identified. Patients receiving adjuvant RT (n = 51), defined as RT within the first year of surgery before tumor progression/recurrence (P/R), were compared with those undergoing initial surveillance (n = 179). The primary endpoints were radiographic evidence of P/R and time to P/R from surgery., Results: A total of 230 patients were identified. Fifty-one (22%) patients received upfront adjuvant RT, and 179 (78%) underwent surveillance. Compared with the surveillance group, patients who received adjuvant RT had larger tumors (5.2 cm vs 4.6 cm; P = .04), were more likely to have undergone subtotal resection (65% vs 26%; P < . 01), and more often had bone invasion (18% vs 7%; P = .02). On multivariable analysis, receipt of adjuvant RT was associated with a lower risk of P/R compared with surveillance (hazard ratio, 0.21; 95% confidence interval, 0.11-0.41; P < .01). Patients who initially underwent surveillance and then received salvage RT at time of P/R had a shorter median time to local progression after RT compared with patients who developed local P/R after upfront adjuvant RT (19 vs 64 months, respectively; P < . 01)., Conclusion: Upfront adjuvant RT was associated with improved local control in atypical meningiomas irrespective of extent of initial resection compared with surveillance. Early adjuvant RT should be strongly considered after gross total resection of atypical meningiomas., (Copyright © 2020 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
46. Airborne Aerosol Generation During Endonasal Procedures in the Era of COVID-19: Risks and Recommendations.
- Author
-
Workman AD, Jafari A, Welling DB, Varvares MA, Gray ST, Holbrook EH, Scangas GA, Xiao R, Carter BS, Curry WT, and Bleier BS
- Subjects
- Betacoronavirus, COVID-19, Cadaver, Endoscopy, Humans, Pandemics, Particle Size, Personal Protective Equipment, Prospective Studies, Risk Factors, SARS-CoV-2, Aerosols adverse effects, Coronavirus Infections transmission, Nose virology, Otorhinolaryngologic Surgical Procedures, Pneumonia, Viral transmission
- Abstract
Objective: In the era of SARS-CoV-2, the risk of infectious airborne aerosol generation during otolaryngologic procedures has been an area of increasing concern. The objective of this investigation was to quantify airborne aerosol production under clinical and surgical conditions and examine efficacy of mask mitigation strategies., Study Design: Prospective quantification of airborne aerosol generation during surgical and clinical simulation., Setting: Cadaver laboratory and clinical examination room., Subjects and Methods: Airborne aerosol quantification with an optical particle sizer was performed in real time during cadaveric simulated endoscopic surgical conditions, including hand instrumentation, microdebrider use, high-speed drilling, and cautery. Aerosol sampling was additionally performed in simulated clinical and diagnostic settings. All clinical and surgical procedures were evaluated for propensity for significant airborne aerosol generation., Results: Hand instrumentation and microdebridement did not produce detectable airborne aerosols in the range of 1 to 10 μm. Suction drilling at 12,000 rpm, high-speed drilling (4-mm diamond or cutting burs) at 70,000 rpm, and transnasal cautery generated significant airborne aerosols ( P < .001). In clinical simulations, nasal endoscopy ( P < .05), speech ( P < .01), and sneezing ( P < .01) generated 1- to 10-μm airborne aerosols. Significant aerosol escape was seen even with utilization of a standard surgical mask ( P < .05). Intact and VENT-modified (valved endoscopy of the nose and throat) N95 respirator use prevented significant airborne aerosol spread., Conclusion: Transnasal drill and cautery use is associated with significant airborne particulate matter production in the range of 1 to 10 μm under surgical conditions. During simulated clinical activity, airborne aerosol generation was seen during nasal endoscopy, speech, and sneezing. Intact or VENT-modified N95 respirators mitigated airborne aerosol transmission, while standard surgical masks did not.
- Published
- 2020
- Full Text
- View/download PDF
47. IDH-mutant gliomas harbor fewer regulatory T cells in humans and mice.
- Author
-
Richardson LG, Nieman LT, Stemmer-Rachamimov AO, Zheng XS, Stafford K, Nagashima H, Miller JJ, Kiyokawa J, Ting DT, Wakimoto H, Cahill DP, Choi BD, and Curry WT
- Subjects
- Animals, Humans, Isocitrate Dehydrogenase genetics, Mice, Mutation, T-Lymphocytes, Regulatory, Brain Neoplasms genetics, Glioma genetics
- Abstract
The metabolic gene isocitrate dehydrogenase 1 ( IDH1 ) is commonly mutated in lower grade glioma (LGG) and secondary glioblastoma (GBM). Regulatory T cells (Tregs) play a significant role in the suppression of antitumor immunity in human glioma. Given the importance of Tregs in the overall framework of designing immune-based therapies, a better understanding on their association with IDH mutational status remains of critical clinical importance. Using multispectral imaging analysis, we compared the incidence of Tregs in IDH-mutant and IDH wild-type glioma from patient tumor samples of LGG. An orthotopic IDH-mutant murine model was generated to evaluate the role of mutant IDH on Treg infiltration by immunohistochemistry. When compared to IDH wild-type controls, Tregs are disproportionally underrepresented in mutant disease, even when taken as a proportion of all infiltrating T cells. Our findings suggest that therapeutic agents targeting Tregs may be more appropriate in modulating the immune response to wild-type disease., (© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.)
- Published
- 2020
- Full Text
- View/download PDF
48. Endonasal instrumentation and aerosolization risk in the era of COVID-19: simulation, literature review, and proposed mitigation strategies.
- Author
-
Workman AD, Welling DB, Carter BS, Curry WT, Holbrook EH, Gray ST, Scangas GA, and Bleier BS
- Subjects
- Aerosols, Betacoronavirus isolation & purification, COVID-19, Cadaver, Coronavirus Infections epidemiology, Coronavirus Infections prevention & control, Endoscopy instrumentation, Humans, Otolaryngology instrumentation, Pandemics prevention & control, Personal Protective Equipment virology, Pneumonia, Viral epidemiology, Pneumonia, Viral prevention & control, SARS-CoV-2, Sneezing, Coronavirus Infections transmission, Endoscopy adverse effects, Infectious Disease Transmission, Patient-to-Professional prevention & control, Nose Diseases diagnosis, Nose Diseases surgery, Nose Diseases virology, Otolaryngology standards, Pneumonia, Viral transmission
- Abstract
Background: International experience with coronavirus 2019 (COVID-19) suggests it poses a significant risk of infectious transmission to skull base surgeons, due to high nasal viral titers and the unknown potential for aerosol generation during endonasal instrumentation. The purpose of this study was to simulate aerosolization events over a range of endoscopic procedures to obtain an evidence-based aerosol risk assessment., Methods: Aerosolization was simulated in a cadaver using fluorescein solution (0.2 mg per 10 mL) and quantified using a blue-light filter and digital image processing. Outpatient sneezing during endoscopy was simulated using an intranasal atomizer in the presence or absence of intact and modified surgical mask barriers. Surgical aerosolization was simulated during nonpowered instrumentation, suction microdebrider, and high-speed drilling after nasal fluorescein application., Results: Among the outpatient conditions, a simulated sneeze event generated maximal aerosol distribution at 30 cm, extending to 66 cm. Both an intact surgical mask and a modified VENT mask (which enables endoscopy) eliminated all detectable aerosol spread. Among the surgical conditions, cold instrumentation and microdebrider use did not generate detectable aerosols. Conversely, use of a high-speed drill produced significant aerosol contamination in all conditions tested., Conclusion: We confirm that aerosolization presents a risk to the endonasal skull base surgeon. In the outpatient setting, use of a barrier significantly reduces aerosol spread. Cold surgical instrumentation and microdebrider use pose significantly less aerosolization risk than a high-speed drill. Procedures requiring drill use should carry a special designation as an "aerosol-generating surgery" to convey this unique risk, and this supports the need for protective personal protective equipment., (© 2020 ARS-AAOA, LLC.)
- Published
- 2020
- Full Text
- View/download PDF
49. Exploring Predictors of Response to Dacomitinib in EGFR -Amplified Recurrent Glioblastoma.
- Author
-
Chi AS, Cahill DP, Reardon DA, Wen PY, Mikkelsen T, Peereboom DM, Wong ET, Gerstner ER, Dietrich J, Plotkin SR, Norden AD, Lee EQ, Nayak L, Tanaka S, Wakimoto H, Lelic N, Koerner MV, Klofas LK, Bertalan MS, Arrillaga-Romany IC, Betensky RA, Curry WT, Borger DR, Balaj L, Kitchen RR, Chakrabortty SK, Valentino MD, Skog J, Breakefield XO, Iafrate AJ, and Batchelor TT
- Abstract
Purpose: Despite the high frequency of EGFR genetic alterations in glioblastoma (GBM), EGFR-targeted therapies have not had success in this disease. To improve the likelihood of efficacy, we targeted adult patients with recurrent GBM enriched for EGFR gene amplification, which occurs in approximately half of GBM, with dacomitinib, a second-generation, irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that penetrates the blood-brain barrier, in a multicenter phase II trial., Patients and Methods: We retrospectively explored whether previously described EGFR extracellular domain (ECD)-sensitizing mutations in the context of EGFR gene amplification could predict response to dacomitinib, and in a predefined subset of patients, we measured post-treatment intratumoral dacomitinib levels to verify tumor penetration., Results: We found that dacomitinib effectively penetrates contrast-enhancing GBM tumors. Among all 56 treated patients, 8 (14.3%) had a clinical benefit as defined by a duration of treatment of at least 6 months, of whom 5 (8.9%) remained progression free for at least 1 year. Presence of EGFRvIII or EGFR ECD missense mutation was not associated with clinical benefit. We evaluated the pretreatment transcriptome in circulating extracellular vesicles (EVs) by RNA sequencing in a subset of patients and identified a signature that distinguished patients who had durable benefit versus those with rapid progression., Conclusion: While dacomitinib was not effective in most patients with EGFR -amplified GBM, a subset experienced a durable, clinically meaningful benefit. Moreover, EGFRvIII and EGFR ECD mutation status in archival tumors did not predict clinical benefit. RNA signatures in circulating EVs may warrant investigation as biomarkers of dacomitinib efficacy in GBM., Competing Interests: The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/po/author-center. Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments). Andrew S. ChiEmployment: Neon Therapeutics, Mirati Therapeutics Consulting or Advisory Role: Cota Healthcare Patents, Royalties, Other Intellectual Property: Fused Bicyclic Heterocycles as Therapeutic Agents (inventor) provisional patent application No. 62/742,041 filed on October 5, 2018 Travel, Accommodations, Expenses: AbbVieDaniel P. CahillHonoraria: Merck Consulting or Advisory Role: Eli Lilly Travel, Accommodations, Expenses: MerckDavid A. ReardonHonoraria: Merck, Novartis, Novocure, Regeneron Pharmaceuticals, Bristol-Myers Squibb, Oncorus, Agenus, EMD Serono, Merck KGaA, Taiho Pharmaceutical, Advantagene, Bayer AG, Delmar Pharmaceuticals, Imvax Consulting or Advisory Role: Merck, Novartis, Novocure, Regeneron Pharmaceuticals, Bristol-Myers Squibb, Oncorus, Agenus, EMD Serono, Merck KGaA, Taiho Pharmaceutical, Delmar Pharmaceuticals, Advantagene, Bayer AG, Imvax Research Funding: Celldex (Inst), Incyte (Inst), Agenus (Inst), EMD Serono (Inst), Acerta Pharma (Inst), Omniox (Inst)Patrick Y. WenConsulting or Advisory Role: Agios, AstraZeneca, Vascular Biogenics, Immunomic Therapeutics, Kayatec, Puma Biotechnology, Taiho Pharmaceutical, Deciphera, VBI Vaccines, Tocagen, Bayer AG, Blue Earth Diagnostics, Karyopharm, Deciphera, Voyager, Taiho Pharmaceutical, QED, Imvax, Elevate Bio, Integral Health Speakers’ Bureau: Merck, Prime Oncology Research Funding: Agios (Inst), AbbVie (Inst), AstraZeneca (Inst), Merck (Inst), Novartis (Inst), Oncoceutics (Inst), Eli Lilly (Inst), AstraZeneca (Inst), BeiGene (Inst), Kazia (Inst), MediciNova (Inst), Vacular Biogenics (Inst), VBI Vaccines (Inst), Puma Biotechnology (Inst), Celgene (Inst), Bayer AG (Inst)Tom MikkelsenHonoraria: Roche, Genentech Travel, Accommodations, Expenses: Roche, GenentechDavid M. PeereboomConsulting or Advisory Role: Orbus Therapeutics Research Funding: Stemline Therapeutics (Inst), Pfizer (Inst), Novartis (Inst), Neonc Technologies (Inst), Orbus Therapeutics (Inst), Bristol-Myers Squibb (Inst), Genentech (Inst), Roche (Inst), Mylan (Inst) Travel, Accommodations, Expenses: Stemline TherapeuticsEric T. WongHonoraria: Novocure, UpToDate, Advanced Medical, ZaiLab Consulting or Advisory Role: Turning Point Therapeutics Research Funding: Novocure, Orbus, Vascular Biogenics, Five Prime Therapeutics, PlexxikonElizabeth R. GerstnerConsulting or Advisory Role: Blue Earth Diagnostics, MyoKardia (I), Array BioPharma (I)Jorg DietrichHonoraria: Unum Therapeutics, Blue Earth Diagnostics Consulting or Advisory Role: Blue Earth Diagnostics Patents, Royalties, Other Intellectual Property: UpToDateScott R. PlotkinStock and Other Ownership Interests: NFlection Therapeutics, NF2 Therapeutics Consulting or Advisory Role: AstraZeneca, NFlection Therapeutics Research Funding: Takeda Pharmaceuticals (Inst) Travel, Accommodations, Expenses: NFlection Therapeutics Uncompensated Relationships: Pfizer (Inst)Andrew D. NordenEmployment: Cota Healthcare, Oncology Analytics Leadership: Cota Healthcare, Oncology Analytics Stock and Other Ownership Interests: Cota Healthcare, Oncology AnalyticsEudocia Q. LeeHonoraria: Medlink Consulting or Advisory Role: Eli Lilly, Prime Oncology Patents, Royalties, Other Intellectual Property: Royalties from Wolters Kluwer for Up to DateLakshmi NayakTravel, Accommodations, Expenses: Bristol-Myers SquibbShota TanakaResearch Funding: Ono Pharmaceutical, Sumitomo Dainippon, Eisai Patents, Royalties, Other Intellectual Property: P2019-095102Mara V. KoernerEmployment: Cygnal Therapeutics, Ultivue Stock and Other Ownership Interests: Cygnal Therapeutics, Ultivue Research Funding: Cygnal Therapeutics, UltivueIsabel C. Arrillaga-RomanyHonoraria: Merck Consulting or Advisory Role: Insys Therapeutics, Karus Therapeutics, Agios, Boehringer Ingelheim, FORMA Therapeutics Research Funding: Astex PharmaceuticalsRebecca A. BetenskyConsulting or Advisory Role: Biogen, Reata, Alexion Pharmaceuticals, Quark, Intracellular Therapies Expert Testimony: TEVA Pharmaceuticals Industries, AmarinDarrel R. BorgerEmployment: Takeda Pharmaceuticals Stock and Other Ownership Interests: Takeda PharmaceuticalsLeonora BalajEmployment: Exosome Diagnostics (I) Leadership: Exosome Diagnostics (I) Stock and Other Ownership Interests: Exosome Diagnostics (I) Patents, Royalties, Other Intellectual Property: Massachusetts General Hospital (MGH) has intellectual property on exosome cancer diagnostics and inventor and receives royalties (I); co-inventor and receive royalties from MGH; many patents through Exosome Diagnostics (I)Robert R. KitchenEmployment: Exosome Diagnostics Stock and Other Ownership Interests: Exosome Diagnostics Patents, Royalties, Other Intellectual Property: Several patents pending for inventions while employed at Exosome DiagnosticsSudipto K. ChakraborttyEmployment: Exosome Diagnostics Stock and Other Ownership Interests: Exosome Diagnostics Research Funding: Exosome Diagnostics Patents, Royalties, Other Intellectual Property: Patents pending for work at Exosome Diagnostics Travel, Accommodations, Expenses: Exosome DiagnosticsMichael D. ValentinoEmployment: Exosome Diagnostics Stock and Other Ownership Interests: Exosome Diagnostics Research Funding: Exosome Diagnostics Patents, Royalties, Other Intellectual Property: RNA-seq patents as co-discoverer while working at Exosome Diagnostics Travel, Accommodations, Expenses: Exosome DiagnosticsA. John IafrateStock and Other Ownership Interests: Archer Biosciences Consulting or Advisory Role: Debiopharm Group, Chugai Pharma, Roche, Repare Therapeutics, Research Funding: Sanofi Patents, Royalties, Other Intellectual Property: ArcherDx exclusive license to AMP technologyTracy T. BatchelorHonoraria: UpToDate Consulting or Advisory Role: GenomiCare, Amgen Travel, Accommodations, Expenses: GenomiCare No other potential conflicts of interest were reported., (© 2020 by American Society of Clinical Oncology.)
- Published
- 2020
- Full Text
- View/download PDF
50. A Common Rule for Resection of Glioblastoma in the Molecular Era.
- Author
-
Choi BD, Gerstner ER, and Curry WT Jr
- Subjects
- Humans, Temozolomide, Brain Neoplasms, Glioblastoma
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.